While keeping the vial upside down, draw the required testosterone dosage into the syringe, ensuring no air bubbles are present
As real-world practices evolve, dosing strategies often stray from clinical trial protocols
To view or add a comment, sign in How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA Open Access Nephrology Dialysis Transplantation, Volume 40, Issue 10, October 2025, Pages 19771988, Published: 13 May 2025 The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD)
Patients with MCAS may experience: Flushing Urticaria (hives) and itching Gastrointestinal distress Brain fog Tachycardia Headaches Hypotension Respiratory symptoms Anaphylactoid reactions Because mast cells reside throughout connective tissues, symptoms are often multisystem, variable, and unpredictable